Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center

ABSTRACT Objective To compare serum anti-Müllerian hormone (AMH) and other endocrine parameters between patients diagnosed with polycystic ovary syndrome (PCOS) and age-matched ovulatory women. Materials and methods AMH, DHEAS, FSH, LH, PRL, TSH and total testosterone (TT) were prospectively measured in oligo-ovulatory PCOS patients (n = 595) and in ovulatory non-PCOS women (n = 157) referred to a tertiary infertility center. Mean BMI was similar across the two study populations and there were no smokers in the sample. Patients in both groups were further classified into three categories by age: < 25 yrs, 25-34 yrs, and ≥ 35 yrs. Selected clinical and demographic characteristics were tabulated for each group. Results Serum AMH was significantly higher among PCOS patients compared to non-PCOS controls in the non-stratified sample (7.54 ± 5.8 vs. 2.49 ± 2.0 ng/mL, respectively; p < 0.0001), while serum FSH, DHEAS, TSH and prolactin were similar for both groups (p > 0.05). As expected, mean (total) testosterone levels were notably different between PCOS vs. non-PCOS controls (0.84 ± 0.76 vs. 0.43 ± 0.38 ng/mL, respectively; p < 0.001), and mean AMH level was significantly lower in the oldest age category (> 35 yrs) compared to both younger control groups (p < 0.0001). Both DHEAS and total testosterone decreased with age among PCOS patients, although mean serum DHEAS for women age > 35 yrs was significantly lower than DHEAS measured in younger women with PCOS (p < 0.02). For PCOS patients, AMH remained relatively stable irrespective of age. Conclusion Although AMH can serve as a satisfactory marker of ovarian reserve, for PCOS patients the expected decline in AMH associated with reproductive aging appears attenuated despite ovarian senescence. In contrast, mean DHEAS levels were markedly lower among older PCOS women (> 35 yrs) compared to younger PCOS patients.

[1]  A. P. Walsh,et al.  Impact of Pre-Mixing AMH Serum Samples with Standard Assay Buffer: Ovarian Reserve Estimations and Implications for Clinical IVF Providers , 2016 .

[2]  R. Homburg,et al.  Serum anti‐Mullerian hormone levels across different ethnic groups: a cross‐sectional study , 2015, BJOG : an international journal of obstetrics and gynaecology.

[3]  A. Duhamel,et al.  The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome. , 2015, Human reproduction.

[4]  D. Albertini,et al.  Relative importance of AMH and androgens changes with aging among non-obese women with polycystic ovary syndrome , 2015, Journal of Ovarian Research.

[5]  R. Homburg,et al.  Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimüllerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. , 2015, Fertility and sterility.

[6]  H. Sangi-Haghpeykar,et al.  Antimullerian hormone levels are inversely associated with body mass index (BMI) in women with polycystic ovary syndrome , 2015, Journal of Assisted Reproduction and Genetics.

[7]  A. Duhamel,et al.  Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles. , 2014, Human reproduction.

[8]  M. Maidarti,et al.  Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients , 2014, Journal of Assisted Reproduction and Genetics.

[9]  E. Stener-Victorin,et al.  Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimüllerian hormone, free testosterone, and glucose disposal rate. , 2014, Fertility and sterility.

[10]  S. Chun.  Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome , 2014, Clinical and experimental reproductive medicine.

[11]  D. Hougaard,et al.  The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. , 2014, Human reproduction.

[12]  M. Oncul,et al.  Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms , 2014, Journal of Assisted Reproduction and Genetics.

[13]  M. Koong,et al.  Can high serum anti-Müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients? , 2013, Clinical and experimental reproductive medicine.

[14]  D. Dewailly,et al.  The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome , 2013, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[15]  P. Timms,et al.  The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. , 2013, Human reproduction.

[16]  D. Seifer,et al.  Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. , 2007, Fertility and sterility.

[17]  B. Fauser,et al.  Antimüllerian hormone serum levels: a putative marker for ovarian aging. , 2002, Fertility and sterility.

[18]  M. Genton,et al.  Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports , 2001, BMC women's health.

[19]  J. Connell,et al.  The long term health consequences of polycystic ovary syndrome , 2000, BJOG : an international journal of obstetrics and gynaecology.

[20]  G. Guyatt,et al.  Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). , 1998, The Journal of clinical endocrinology and metabolism.

[21]  Y. Siow,et al.  Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. , 1997, Fertility and sterility.

[22]  M. Hull.  Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. , 1987, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.